Pediatric Psychopharmacology for Primary Care

Introduction Target Audience Why Now? What Does This Book Contribute? References Part 1— Before Prescribing Chapter 1—Pediatric Psychopharmacology Principles Core Pediatric Psychopharmacology Principles Additional Pediatric Psychopharmacology Principles Organization and Overview Chapter 2—Conceptual Framework for Prescribing Psychotropic Medications Rationale for the Conceptual Framework Group 1 Medications for Attention-Deficit/Hyperactivity Disorder, Anxiety, and Depression Group 2 Medications Group 3 Medications References Chapter 3—Making a Diagnosis Overview Diagnosis of Common Disorders: ADHD, Anxiety Disorders, and Depression Diagnosis of Common Comorbidities of ADHD, Anxiety Disorders, and Depression Recognizing Other Psychiatric Disorders Determine if Medication Is Indicated Recognize Need for Referral References Chapter 4—Before Prescribing Formulation Feedback Nonmedication Interventions Informed Consent Specific Consent Issues Off-label Prescribing US Food and Drug Administration Boxed Warnings Triage for Psychiatric and Social Emergencies Important Considerations for Safe and Effective Prescribing References Part 2 — Group 1 Medications for Specific Diagnoses: Attention-Deficit/Hyperactivity Disorder, Anxiety, and Depression Chapter 5—Group 1 Medications for Attention-Deficit/Hyperactivity Disorder Clinical Comments General Guidance Methylphenidate Amphetamine Guanfacine Clonidine Atomoxetine Viloxazine Summary References Chapter 6—Group 1 Medications for Anxiety and Depression General Guidance Group 1 Selective Serotonin Reuptake Inhibitors Group 1 Serotonin and Norepinephrine Reuptake Inhibitor: Duloxetine Summary References Part 3 — Group 2 and Group 3 Medications Chapter 7—Group 2 Medications: FDA-Approved Antipsychotics and Mood Stabilizers Rationale Antipsychotics The Mood Stabilizer Lithium Summary References Chapter 8—Group 3 Medications: Others Commonly Prescribed Other Antidepressants Other Antipsychotics Other Mood Stabilizers Anxiolytics Sleep Aids Future Considerations References Part 4—After Prescribing: Midcourse Corrections Chapter 9—Fine Tuning Treatment Reevaluate Therapies Reevaluate Medication Discontinuing Group 1 Medications Switching Group 1 Medications When to Consider Group 2 Antipsychotics or Lithium When to Consider Group 3 Medications Without FDA Approval for Use in Youth When to Consider Drug Levels or Genetic Testing Can Genotyping Improve Medication Response? When to Consider Consultation or a Second Opinion References Chapter 10—Managing Treatment Impasses Reassess Diagnoses Complex Psychosocial Presentations Expert Consultation or Referral Reference Appendixes Appendix A–Assessment and Symptom Monitoring Tools Appendix B–Resources for Clinicians Appendix C–Training Resources for Clinicians Appendix D–Quality Ratings for Psychotherapies and Efficacy Data for Medications Appendix E–Resources for Caregivers Index